Kobayashi, Mana
Kageyama, Yutaro
Ando, Takashi http://orcid.org/0000-0001-7287-635X
Sakamoto, Junko
Kimura, Shohji
Clinical trials referenced in this document:
Documents that mention this clinical trial
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
https://doi.org/10.1007/s10157-021-02035-6
Funding for this research was provided by:
Zenyaku Kogyo Co., Ltd
Chugai Pharmaceutical
Article History
Received: 19 October 2020
Accepted: 20 February 2021
First Online: 1 April 2021
Declarations
:
: Mana Kobayashi, Yutaro Kageyama, Takashi Ando, Junko Sakamoto, and Shohji Kimura are employees of Zenyaku Kogyo Co., Ltd.
: All procedures performed in studies involving human participants were conducted in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: As this was post-marketing surveillance, it was not necessary to obtain approval from an ethical review board or patient informed consent, based on Japanese regulatory guidelines for Good Post-marketing Surveillance Practice [CitationRef removed].